HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$38.46

Market cap

$5.07B

P/E Ratio

22.1

Dividend/share

N/A

EPS

$1.74

Enterprise value

$6.35B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
Halozyme Therapeutics's quick ratio has soared by 156% YoY
The company's revenue has surged by 59% YoY and by 10% QoQ
The company's equity has surged by 129% QoQ but it fell by 48% YoY
HALO's net income is down by 36% year-on-year but it is up by 29% since the previous quarter
The debt has grown by 20% YoY
Halozyme Therapeutics's gross margin has decreased by 5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
131.92M
Market cap
$5.07B
Enterprise value
$6.35B
Valuations
Price to earnings (P/E)
22.1
Price to book (P/B)
33.53
Price to sales (P/S)
6.55
EV/EBIT
20.41
EV/EBITDA
16.34
EV/Sales
8.21
Earnings
Revenue
$773.65M
EBIT
$311.01M
EBITDA
$388.42M
Free cash flow
$318.79M
Per share
EPS
$1.74
Free cash flow per share
$2.42
Book value per share
$1.15
Revenue per share
$5.87
TBVPS
$6.7
Balance sheet
Total assets
$1.81B
Total liabilities
$1.66B
Debt
$1.5B
Equity
$151.03M
Working capital
$649.35M
Liquidity
Debt to equity
9.91
Current ratio
6.58
Quick ratio
5.11
Net debt/EBITDA
3.28
Margins
EBITDA margin
50.2%
Gross margin
77.4%
Net margin
30.2%
Operating margin
39.6%
Efficiency
Return on assets
13%
Return on equity
193.3%
Return on invested capital
15.4%
Return on capital employed
18.4%
Return on sales
40.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-0.03%
1 week
-2.88%
1 month
-9.91%
1 year
-0.47%
YTD
-32.41%
QTD
6.63%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$773.65M
Gross profit
$598.97M
Operating income
$306.06M
Net income
$233.71M
Gross margin
77.4%
Net margin
30.2%
The net margin has plunged by 60% YoY but it has grown by 17% from the previous quarter
The company's revenue has surged by 59% YoY and by 10% QoQ
HALO's gross profit has soared by 51% YoY and by 10% QoQ
HALO's net income is down by 36% year-on-year but it is up by 29% since the previous quarter

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
22.1
P/B
33.53
P/S
6.55
EV/EBIT
20.41
EV/EBITDA
16.34
EV/Sales
8.21
HALO's EPS is down by 33% year-on-year but it is up by 31% since the previous quarter
The stock's price to earnings (P/E) is 22% less than its last 4 quarters average of 28.5
The company's equity has surged by 129% QoQ but it fell by 48% YoY
HALO's price to book (P/B) is 37% lower than its last 4 quarters average of 52.9
The company's revenue has surged by 59% YoY and by 10% QoQ
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 13.3 and 24% lower than the last 4 quarters average of 8.6

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has soared by 66% from the previous quarter and by 36% YoY
Halozyme Therapeutics's return on assets has shrunk by 54% YoY but it has increased by 29% QoQ
HALO's return on sales is down by 19% year-on-year but it is up by 15% since the previous quarter
HALO's return on invested capital is up by 18% since the previous quarter and by 4.8% year-on-year

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 9% higher than its total liabilities
Halozyme Therapeutics's quick ratio has soared by 156% YoY
The company's current ratio has surged by 142% YoY
Halozyme Therapeutics's debt to equity has soared by 133% YoY but it has plunged by 56% from the previous quarter
The company's equity has surged by 129% QoQ but it fell by 48% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.